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The role of phosphodiesterase 4B in IL-8/LTB4-induced human 
neutrophil chemotaxis evaluated with
a phosphodiesterase 4B inhibitor
PDE4B was previously shown to be a dominant PDE4 sub-
type of neutrophils. However, its physiological role in the 
neutrophil function has not been evaluated. In this study, 
the inhibitory eﬀ ects of a phosphodiesterase 4B (PDE4B)-
selective inhibitor (compound A) and subtype non-selective 
PDE4 inhibitors (roﬂ umilast and cilomilast) were evaluated 
in human peripheral blood cells. Compound A, roﬂ umilast 
and cilomilast in a similar manner inhibited TNF-a produc-
tion by LPS-stimulated human mononuclear cells. Howev-
er, the inhibitory eﬀ ect of compound A on IL-8 or LTB4-in-
duced chemotactic response of neutrophils was modest 
even at the highest concentration (10 µmol L–1), whereas ro-
ﬂ umilast and cilomilast inhibited IL-8 or LTB4-induced neu-
trophil chemotaxis. Our results suggest that PDE4B does 
not play an important role during the chemotactic response 
of human neutrophils.
Keywords: phosphodiesterase 4B, phosphodiesterase 4D, 
mo nonuclear cells, neutrophils
Eleven structurally related but functionally distinct gene families (PDE1 to PDE11) 
have been identiﬁ ed in mammalians and comprise the PDE superfamily (1, 2). PDE4 is a 
cAMP-speciﬁ c phosphodiesterase and has been shown to play key roles in the regulation 
of a number of inﬂ ammatory processes such as cell tracking, release of inﬂ ammatory me-
diators and immune cell proliferation. The PDE4 family is composed of 4 diﬀ erent genes, 
PDE4A, B, C, and D, which are distinguished from other PDEs by a unique N terminus, 
which is involved in intracellular targeting and regulating catalytic activity. 
The physiological role of PDE4 subtypes in human blood leukocytes has been inves-
tigated mainly in monocytes and T cells but not in neutrophils. It has been suggested that 
PDE4A and/or PDE4B play key roles in the LPS-induced TNF-α release from monocyte and 
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Another study using a gene silencing method has shown that PDE4A, PDE4B and PDE4D 
have overall non-redundant, but complementary, time-dependent roles in the anti-CD3/
CD28 stimulation induced CD4+ T cell cytokine release and proliferation (4). On the other 
hand, the physiological role of PDE4 subtypes in human neutrophils has not been investi-
gated. It was reported that the mRNA expression level of each PDE4 subtype in human 
neutrophil was PDE4B (99.7 %), PDE4D (0.3 %) while PDE4A and C were almost absent (5). 
The dominant expression of PDE4B in human neutrophils suggested that PDE4B, but not 
PDE4A, PDE4C or PDE4D, has an important role in cellular control of cAMP in human 
neutrophils. However, functional studies are necessary to elucidate the physiological role 
of PDE4B in human neutrophils during the inﬂ ammatory process. In order to elucidate the 
physiological function of proteins, gene knockdown technology using the siRNA method 
is generally used; however, this method is diﬃ  cult to apply to neutrophils due to their 
shortlife nature. 
We have recently identiﬁ ed and reported on a PDE4B-selective inhibitor, compound 
A. The inhibitory activities of compound A and subtype non-selective PDE4 inhibitors 
(roﬂ umilast and cilomilast) for PDE4B and PDE4D were directly compared in our previ-
ous study (6). The IC50 values for human PDE4B, PDE4D and selectivity (IC50 value for 
PDE4D/IC50 value for PDE4B) were as follows: compound A (5.5 and 440 nmol L–1, 80-
fold), roﬂ umilast (0.49 and 0.49 nmol L–1, 1-fold), and cilomilast (73 and 21 nmol L–1, 
0.3-fold) (6).
In the present study, we investigated the physiological role of PDE4B in human neu-
trophils by evaluating the inhibitory eﬀ ect of compound A on human neutrophil chemo-
taxis and comparing it to that of subtype non-selective PDE4 inhibitors.
EXPERIMENTAL
Reagents
Compound A (2-[4-[[2-(3-ﬂ uoro-4-methoxy-phenyl)-7,8-dihydro-6H-thiopyrano [3,2-d] 
pyrimidin-4-yl]amino]phenyl] acetic acid), roﬂ umilast and cilomilast were synthesized at 
Daiichi Sankyo Chemical Research Laboratories (Japan). LPS (Escherichia coli O55:B5), dex-
tran (Mr = 450,000-650,000), leukotriene B4 (LTB4) and sodium dodecyl sulfate (SDS) were 
obtained from Sigma-Aldrich (USA). RPMI 1640 without phenol red medium, a human 
TNF-a ELISA kit and a human IL-6 ELISA kit were purchased from Life Technology 
(USA). Calcein-AM was purchased from Dojindo Laboratories (Japan) and Ficoll-Paque 
Plus was purchased from GE Healthcare Japan (Japan). Human IL-8 was purchased from 
R&D systems (USA).
Preparation of cells 
Human peripheral blood (30 mL) was obtained from healthy volunteers (aged 43–44 
years, both male and female). The volunteers were forbidden to take any medicine for 
seven days before blood collection. All experimental procedures were approved by the 
Institutional Ethical Commi ee at Daiichi Sankyo and performed in accordance with the 
guidelines. Mononuclear cells and neutrophils were separated by a Ficoll gradient protocol 
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according to the manufacturer’s instructions. Brieﬂ y, erythrocyte sedimentation was per-
formed by adding 3 mL of dextran dissolved in PBS (6 %) to 30 mL of heparinized whole 
blood and kept for 30 min at room temperature. The supernatant was carefully collected 
and layered onto 20 mL of Ficoll-Paque Plus and centrifuged at 400xg for 30 min at room 
temperature. A er centrifugation, mononuclear cells and neutrophils were obtained in the 
interface and pellet, respectively. The cells were hemolyzed by adding 2 mL of 0.2 % NaCl 
solution and then incubation on ice for 1 min, followed by isotonization. The purity of 
neutrophils by this sedimentation method was > 90 % pure by morphology. Mononuclear 
cells and neutrophils were washed twice and re-suspended at 4 × 106 cells mL–1 in culture 
medium (RPMI 1640 with 2 % FBS).
LPS-induced cytokine release from mononuclear cells
An LPS-induced cytokine release assay was performed as previously described (7). 
LPS-containing culture medium (200 ng mL–1) with the test compound (2-fold of the ﬁ nal 
concentration) was added to a 96-well tissue culture plate (100 mL per well). Mononuclear 
cells (2 × 106 cells mL–1) were added to the well (100 mL per well) and incubated for 18 h at 
37 °C. A er brief centrifugation, the supernatant was collected and kept at −20 °C until use. 
The concentration of TNF-a and IL-6 in the supernatant was measured using an ELISA kit 
according to the manufacturer’s instructions and the percent concentration of each sample 
compared to the control samples was calculated.
Neutrophil chemotaxis assay
A neutrophil chemotaxis assay was performed as previously described (8). Neutro-
phil suspensions (4 × 106 cells mL–1) were incubated with 5 mmol L–1 calcein-AM for 30 min 
at 37 °C. The cells were washed twice with ice-cold culture medium and re-suspended 
at 2 × 106 cells mL–1. Test compounds (roﬂ umilast 0.001, 0.01, 0.1 and 1.0 mmol L–1, com-
pound A and cilomilast 0.01, 0.1, 1.0 and 10 mmol L–1 in DMSO) were added (1/1,000 
volume) to each cell suspension and 75 mL of the cell suspension with test compounds 
was loaded into the upper well of each transwell, followed by pre-incubation at 37 °C for 
30 min. IL-8 (10 ng mL–1) or LTB4 (1 ng mL–1) was loaded into the lower well of the tran-
swell plate (275 mL) and pre-incubated at 37 °C for 30 min. A chemotaxis assay was 
started by carefully placing the upper well onto the lower well and the transwell plate 
was incubated for 40 min at 37 °C. The chemotaxis assay was terminated by separating 
the upper well from the lower well. The cells in the lower well were completely lysed by 
adding 10 mL of 10 % SDS aqueous solution. The migrated cells were quantiﬁ ed by mea-
suring calcein ﬂ uorescein of the cell lysate (excitation 485 nm/emission 535 nm) using a 
microplate reader (PerkinElmer Inc., USA). Vehicle-treated wells served as controls and 
the percent inhibitions of test compound-treated wells were calculated a er correction 
with blank wells.
Data analysis
The mean and the standard error (SE) were calculated. The IC50 value was calculated 
and a variable-slope sigmoidal dose-response curve was ﬁ  ed using the GraphPad Prism 
version 5.04 (GraphPad So ware).
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RESULTS AND DISCUSSION
Inhibitory eﬀ ect of compound A on LPS-induced TNF-α release from mononuclear cells
First, we tested the inhibitory eﬀ ect of compound A on human mononuclear cells. It 
was previously reported that subtype non-selective PDE4 inhibitors strongly suppressed 
LPS-stimulated TNF-a release but IL-1b or IL-6 release were partial or absent from human 
monocytes (9, 10). Roﬂ umilast and cilomolast inhibited the TNF-a production in a concen-
tration-dependent manner (Fig. 1a) while the inhibitory eﬀ ect on IL-6 production was ab-
sent (Fig. 1b). Similarly, compound A inhibited TNF-a production by LPS-stimulated 
mononuclear cells in a concentration-dependent manner (Fig. 1a) but did not inhibit IL-6 
production (Fig. 1b). Compound A showed the same inhibitory proﬁ les on LPS-stimulated 
cytokine release from mononuclear cells as subtype non-selective PDE4 inhibitors.
Inhibitory eﬀ ect of compound A on human neutrophil chemotaxis
Next, we investigated the inhibitory eﬀ ect of compound A on neutrophil migration. 
Roﬂ umilast and cilomilast inhibited IL-8-induced neutrophil chemotaxis in a concentra-
tion dependent manner (Fig. 2a). In contrast, compound A slightly inhibited the IL-8-in-
duced chemotactic response of neutrophil cells and the inhibitory eﬀ ect was modest even 
at the highest concentration (10 mmol L–1) (Fig. 2a). In order to determine whether this weak 
inhibitory eﬀ ect of compound A on neutrophil chemotaxis is speciﬁ c for IL-8-induced 
chemotaxis or not, we subsequently tested the inhibitory eﬀ ect of compound A on LTB4-
induced neutrophil migration. The inhibitory eﬀ ect of compound A on LTB4-induced che-
motaxis was limited while roﬂ umilast and cilomilast inhibited neutrophil migration ef-
fectively (Fig. 2, Table I).
It was a surprise that the inhibitory eﬀ ect of compound A on IL-8 or LTB4-induced 
neutrophil migration was weak. It has been suggested that the inhibitory eﬀ ect of subtype 
non-selective PDE4 inhibitors on neutrophils is mainly due to an inhibitory eﬀ ect on 
Fig. 1. Percent inhibition by compounds in LPS-induced cytokine release from human mononuclear 
cells vs. controls: a) TNF-a, b) IL-6. Data is shown as mean ± SE (n = 3).
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Fig. 2. Percent inhibition by compounds in: a) IL-8 or b) LTB4-induced human neutrophil chemotaxis 
vs. controls. Data is shown as mean ± SE (n = 3).
Table I. Summary of in vitro proﬁ les of compound A
Subject
IC50 (nmol L–1)a 
Compound A Roﬂ umilast Cilomilast
LPS-induced TNF-a release from mononuclear cells 34 ± 14 0.66 ± 0.16 55 ± 14
IL-8-induced neutrophil chemotaxis > 10,000 32 ± 25 110 ± 67
LTB4-induced neutrophil chemotaxis > 10,000 250 ± 78 2,700 ± 450
a Mean ± SE, n = 3.
PDE4B considering the predominant expression of PDE4B in human neutrophils over 
other PDE4 subtypes (5). As PDE4D is expressed in neutrophils, even if small, it might be 
possible that a small amount of PDE4D, not PDE4B, may control neutrophil migration. This 
discrepancy between the expression level and functional importance of PDE4 subtypes 
might be explained by the subcellular compartmentalized regulation of cAMP concentra-
tion controlled by localized PDE subtype enzymes. It was recently reported that cells 
regulate their intracellular levels of cAMP in a highly compartmentalized manner (1, 11). 
It is possible that the PDE4D-controlled cAMP level in a speciﬁ c compartment is critical 
for the regulation of neutrophil chemotaxis.
In order to elucidate the functional importance of PDE4 subtypes in human neutro-
phil functions, evaluation of neutrophil function by a pharmacological method using 
PDE4A, C and D-selective inhibitors may be required. However, highly subtype-selective 
inhibitors are not currently available. It is also important to investigate whether other 
functions of neutrophils such as superoxide generation or elastase release are suppressed 
by compound A or not. 
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The clinical importance obtained from the present study is that PDE4B-selective in-
hibitors such as compound A could be anti-inﬂ ammatory drugs that do not inhibit neutro-
phil function but have a strong inhibitory eﬀ ect on inﬂ ammatory cytokine such as IL-1b 
or TNF-a from mononuclear cells, thus having a reduced risk of opportunistic infection.
CONCLUSIONS
The present study has shown for the ﬁ rst time that PDE4B-selective inhibitors do not 
inhibit IL-8 or LTB4-induced neutrophil chemotaxis. This evidence strongly suggests that 
PDE4B does not play an important role during the IL-8 or LTB4-induced chemotactic re-
sponse of human neutrophils. Further studies are required to address the physiological 
role of PDE4 subtypes during human leukocyte activation. 
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